Prior Cesarean Birth and Risk of Uterine Rupture in Second-Trimester Medication Abortions Using Mifepristone and Misoprostol
Obstetrics & Gynecology · 2023
DOI: 10.1097/aog.0000000000005259 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Obstetrics & Gynecology, 2023. Verfasst von Andrea Henkel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Family Planning Services and Research and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Stanford Univ…. Hauptthemen laut MEDLINE: Mifepristone, Misoprostol, Uterine Rupture, Pregnancy Trimester, Second. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To assess the risk difference of uterine rupture when using current mifepristone and misoprostol regimens for second-trimester abortion among individuals with prior cesarean birth compared with those without prior cesarean birth. DATA SOURCES: We searched the terms second trimester, induction, mifepristone, and abortion in PubMed, EMBASE, POPLINE, ClinicalTrials.gov, and Cochrane Library from inception until December 2022. METHODS OF STUDY SELECTION: We included randomized trials and observational studies including a mixed cohort, with and without uterine scar, of individuals at 14–28 weeks of gestation who used mifepristone and misoprostol to end a pregnancy or to manage a fetal death. We excluded case reports, narrative reviews, and studies not published in English. Two reviewers independently screened studies. TABULATION, INTEGRATION, AND RESULTS: Absolute risks with binomial CIs were calculated from pooled data. Using R software, we estimated total risk difference by the Mantel–Haenszel random-effects method without continuity correction. For studies with zero events, a continuity correction of 0.5 was applied for individual risk differences and plotted graphically with forest plots. Statistical heterogeneity was assessed with Higgins I 2 statistics. Funnel plot assessed for publication bias. Of 198 articles identified, 22 met the inclusion criteria: seven randomized trials (n=923) and 15 observational studies (n=6,195). Uterine rupture risk with prior cesarean birth was 1.1% (10/874) (95% CI 0.6–2.1) and without prior cesarean birth was 0.01% (2/6,244) (95% CI 0.0–0.12). The risk difference was 1.23% (95% CI 0.46–2.00, I 2 =0%). Of the 12 reported uterine ruptures, three resulted in hysterectomy. CONCLUSION: Uterine rupture with mifepristone and misoprostol use during second-trimester induction abortion is rare, with the risk increased to 1% in individuals with prior cesarean birth. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42022302626.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Family Planning Services and Research and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California.
Zitieren
APA
Henkel, A., Miller, H. E., Zhang, J., Lyell, D. J., & Shaw, K. A. (2023). Prior Cesarean Birth and Risk of Uterine Rupture in Second-Trimester Medication Abortions Using Mifepristone and Misoprostol. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000005259
Vancouver
Henkel A, Miller HE, Zhang J, Lyell DJ, Shaw KA. Prior Cesarean Birth and Risk of Uterine Rupture in Second-Trimester Medication Abortions Using Mifepristone and Misoprostol. Obstetrics & Gynecology. 2023. doi:10.1097/aog.0000000000005259
BibTeX
@article{Henkel2023,
author = {Henkel, Andrea and Miller, Hayley E and Zhang, Jiaqi and Lyell, Deirdre J and Shaw, Kate A},
title = {Prior Cesarean Birth and Risk of Uterine Rupture in Second-Trimester Medication Abortions Using Mifepristone and Misoprostol},
journal = {Obstetrics & Gynecology},
year = {2023},
doi = {10.1097/aog.0000000000005259}
}
EUVIMED